A-Alpha Bio, Inc.
A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Their mission is to improve human health by accelerating therapeutic discovery through high-throughput data generation and predictive modeling. Based in Seattle, founded in 2017 at the University of Washington, they develop platforms like AlphaSeq and AlphaBind to enable rapid and quantitative measurement of protein interactions, facilitating drug discovery, biologics development, and molecular glue research.
Industries
Nr. of Employees
medium (51-250)
A-Alpha Bio, Inc.
Patents
Products
High-throughput multiplexed protein–protein interaction measurement platform
Experimental platform that builds display libraries, fuses interacting pairs with paired DNA barcodes, and quantifies interaction frequencies by next-generation sequencing to derive affinity measurements at scale.
Sequence-to-affinity machine-learning platform
Computational platform that compiles experimental interaction data to train models which predict binding strength from protein sequence and propose optimized sequences for experimental testing.
High-throughput multiplexed protein–protein interaction measurement platform
Experimental platform that builds display libraries, fuses interacting pairs with paired DNA barcodes, and quantifies interaction frequencies by next-generation sequencing to derive affinity measurements at scale.
Sequence-to-affinity machine-learning platform
Computational platform that compiles experimental interaction data to train models which predict binding strength from protein sequence and propose optimized sequences for experimental testing.
Services
Library-on-library experimental service that produces quantitative binding affinity datasets for thousands to millions of interactions to support model training, binder characterization, and target discovery.
Discovery and engineering of antibodies using phage libraries and high-throughput interaction measurement to deliver sequence-diverse, affinity- and developability-optimized candidates.
High-sensitivity mapping of weak interactions between effector proteins (e.g., ubiquitin ligases) and targets, plus screening approaches to prioritize effector–target pairs for small-molecule induced proximity strategies.
Training and application of ML models that predict binding properties from sequence, and generation of model-guided sequence designs for downstream experimental testing.
End-to-end discovery and engineering services for precision-engineered biologics, including affinity-tuned binders, cross-reactive binders, and dual-specific formats.
Library-on-library experimental service that produces quantitative binding affinity datasets for thousands to millions of interactions to support model training, binder characterization, and target discovery.
Discovery and engineering of antibodies using phage libraries and high-throughput interaction measurement to deliver sequence-diverse, affinity- and developability-optimized candidates.
High-sensitivity mapping of weak interactions between effector proteins (e.g., ubiquitin ligases) and targets, plus screening approaches to prioritize effector–target pairs for small-molecule induced proximity strategies.
Training and application of ML models that predict binding properties from sequence, and generation of model-guided sequence designs for downstream experimental testing.
End-to-end discovery and engineering services for precision-engineered biologics, including affinity-tuned binders, cross-reactive binders, and dual-specific formats.
Expertise Areas
- Protein–protein interaction measurement
- Machine learning for binding-affinity prediction
- Antibody discovery and optimization
- Molecular glue / induced proximity target discovery
Key Technologies
- Library-on-library screening
- Yeast surface display with cell fusion and DNA-barcoding
- Next-generation sequencing readout
- Domain-specific machine learning for sequence-to-binding prediction
News & Updates
A-Alpha Bio was founded in 2017 at the University of Washington’s Institute for Protein Design and Center for Synthetic Biology. They have made progress in harnessing protein-protein interactions to improve human health.
Expansion of collaboration with Amgen to discover molecular glues, leveraging their platforms.
Funding from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to expand their partnership with Lawrence Livermore.
Funding round led by Perceptive Advisors Xontogeny Ventures, with support from Madrona and others.
A-Alpha Bio was founded in 2017 at the University of Washington’s Institute for Protein Design and Center for Synthetic Biology. They have made progress in harnessing protein-protein interactions to improve human health.
Expansion of collaboration with Amgen to discover molecular glues, leveraging their platforms.
Funding from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to expand their partnership with Lawrence Livermore.
Funding round led by Perceptive Advisors Xontogeny Ventures, with support from Madrona and others.